TOUTED to be the best if not the only
option for cures against major diseases,
biotechnology had seemed to falter
midway. Now, however, it is poised for a major breakthrough in treating cancer.
A monoclonal antibody - a product of
medical innovation - will soon have a
go at treating breast cancer. Though the
antibody was developed in 1975, it took
nearly two decades to create a combination along with chemotherapy drugs to
arrive at a possible drug which could
stop cancer in its malignant tracks.
Researchers at the University of California, Los Angeles (UCLA), are now in the process of testing the antibody, which reportedly kills those cancer cells which try to repair damage caused by chemotherapy. Preliminary testing has produced a few positive results and now, largescale international testing is on the cards involving nearly 600 women with advanced stage of breast cancer. Says Dennis Slamon of UCLA of the patients who under-went the initial testing, "These were patients who had failed everything we had to offer, including bone marrow transplantations."
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.